Histopathology of telomerase reverse transcriptase promoter ( TERT ) mutated indeterminate thyroid nodules.
| Autor: | Pinto JO; Department of Internal Medicine, University of Washington, Seattle, WA, USA., Livhits MJ; Section of Endocrine Surgery, UCLA David Geffen School of Medicine, Los Angeles, CA, USA., Yeh MW; Section of Endocrine Surgery, UCLA David Geffen School of Medicine, Los Angeles, CA, USA., Kaykov A; Department of Marketing, Veracyte, South San Francisco, CA, USA., Klopper JP; Department of Medical Affairs, Veracyte, Inc., South San Francisco, CA. USA., Kloos RT; Department of Medical Affairs, Veracyte, Inc., South San Francisco, CA. USA., Alshalalfa M; Department of Research and Development, Veracyte, South San Francisco, CA, USA., Hao Y; Department of Research and Development, Veracyte, South San Francisco, CA, USA., Huang J; Department of Research and Development, Veracyte, South San Francisco, CA, USA., Endo M; Division of Metabolism, Endocrinology, and Nutrition, University of Washington, Seattle, WA, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Journal of clinical & translational endocrinology [J Clin Transl Endocrinol] 2023 Dec 02; Vol. 35, pp. 100329. Date of Electronic Publication: 2023 Dec 02 (Print Publication: 2024). |
| DOI: | 10.1016/j.jcte.2023.100329 |
| Abstrakt: | Objective: The objective of this study was to analyze the risk of malignancy and the histopathology of telomerase reverse transcriptase promoter (TERT) mutated cytologically indeterminate thyroid nodules (ITN). Methods: A PUBMED search of molecularly tested ITN was conducted and data on TERT mutated ITN with histopathology correlation were extracted. Results: Twenty-six manuscripts (published between 2014 and 2022) reported on 77 TERT mutated ITN. Sixty-five nodules were malignant (84 %), with 16 (25 %) described with high-risk histopathology, 5 (8 %) described as low-risk, and most without any description. Isolated TERT mutations were malignant in 26/30 ITNs (87 %) with 9 (35 %) described as high risk and none described as low risk. TERT + RAS mutated ITNs were malignant in 29/34 ITNs (85 %) with 3 (10 %) described as high risk and 4 (14 %) described as low risk. Finally, all 5 TERT + BRAF V600E mutated nodules were malignant and 3/5 (60 %) were described as high risk. Conclusion: TERT mutated ITNs have a high risk of malignancy (84 %), and the current data does not show a difference in malignancy rate between isolated TERT mutations and TERT + RAS co-mutated ITNs. When described, TERT + RAS co-mutated ITNs did not have a higher rate of high-risk histopathology as compared to isolated TERT mutated lesions. Most TERT mutated ITNs did not have a description of histopathology risk and the oncologic outcomes, including rate of recurrence, metastases, and disease specific survival, are unknown. Further data is needed to determine if TERT mutated ITNs should be subjected to aggressive initial treatment. Competing Interests: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Atanas Kaykov, Joshua P. Klopper, Richard T. Kloos, Mohammed Alshalalfa, Yangyang Hao, and Jing Huang are employees and equity owners of Veracyte, Inc. (© 2023 Published by Elsevier Inc.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|